Searching the RRID Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.

Search

Type in a keyword to search

On page 4 showing 61 ~ 80 out of 270 results
Snippet view Table view Download 270 Result(s)
Click the to add this resource to a Collection

http://www.diabetes-translation.org

Centers that are part of an integrated program whose cores support and enhance diabetes type II translation research. The CDTRs aim to enhance the efficiency, productivity, effectiveness and multidisciplinary nature of diabetes translation research.

Proper citation: Centers for Diabetes Translation Research (RRID:SCR_015149) Copy   


  • RRID:SCR_020250

    This resource has 1+ mentions.

https://thesugarscience.org

Interactive digital platform helping scientists who study type 1 diabetes connect, collaborate, and gain funding for their best ideas. All volunteer team has received much positive support from the global population of scientists studying type 1 diabetes, as well as from Beyond Type 1, JDRF, and IPITA. Provides curated conversations, events and technology to scientific T1D focused audience. Non profit entity funded by donations and sponsorships with industry and academic partners to provide unique collaborative benefits and programs to researchers in the T1D academic research community.

Proper citation: thesugarscience (RRID:SCR_020250) Copy   


https://hugeamp.org

Portal enables browsing, searching, and analysis of human genetic information linked to common metabolic diseases and traits, while protecting integrity and confidentiality of underlying data. Aggregates and analyzes genetic association results, epigenomic annotations, and results of computational prediction methods to provide data, visualizations, and tools in open access portal.

Proper citation: Common Metabolic Diseases Knowledge Portal (RRID:SCR_020937) Copy   


http://www.kccmr.org/

This colony provides a national resource of rhesus monkeys and their tissues to carry out research benefiting the scientific community. The RMBRR maintains a colony of monkeys that have been derived to be specific pathogen free for members of both the herpes and retrovirus families. Over its history, the RMBRR has developed specialized management techniques, housing facilities and highly trained staff to avail these purposefully bred laboratory models, which are 93% genetically identical to humans, to researchers worldwide. Historically, this animal model has been instrumental in research involving blood classification, polio vaccine development, and drug safety and efficacy while currently they are the preferred model for studying the mechanisms of immunodeficiency diseases. Their susceptibility to Simian Immunodeficiency Virus and their homology to the human major histocompatibility complex (MHC) Class I, II and TCR genes make them valuable in HIV research. They are currently the models of choice for HIV/AIDS vaccine development and study. Other areas of research include atherosclerosis, myocarditis, alcoholism, diabetes, cancer and aging. The overall objectives of this resource are to improve the resources available at the RMBRR and to conduct resource-relevant research that improves both the health of the rhesus colony and its usefulness for studies of human disease. The Resource and Management Core is responsible for providing animal resources, tissues/biological fluids, cell lines, expert advice and research support to NIH extramural and intramural programs, other federal agencies and to private sponsors. The Resource-Related Research Core conducts research to improve the health of the animals maintained with special emphasis on studies that will enhance the usefulness of the rhesus as a model for studies of human disease.

Proper citation: Rhesus Monkey Breeding and Research (RRID:SCR_008357) Copy   


http://www.diacomp.org

Consortium serving the diabetic complications community that sponsors annual meetings in complications-relevant scientific areas, solicits and funds pilot projects in high impact areas of complications research, and provides resources and data including animal models, protocols and methods, validation criteria, reagents and resources, histology, publications and bioinformatics for researchers conducting diabetic complications research.

Proper citation: Diabetic Complications Consortium (RRID:SCR_001415) Copy   


http://www.bumc.bu.edu/busm-pathology/pathology-core-services/biospecimen-archive-research-core-barc/

Biospecimen repository of normal and diseased human material from a variety of tissues and conditions along with clinical annotation. Both frozen aliquots and paraffin embedded tissue are available. Biospecimens are available to qualified researchers with IRB approval. * Preliminary inquires please contact Cheryl Spencer at cheryl.spencer (at) bmc.org

Proper citation: Boston University Biospecimen Archive Research Core (RRID:SCR_005363) Copy   


https://grade.bsc.gwu.edu/web/grade/home

A comparative study that aims to determine which combination of two medications is best for glycemic control in Type 2 Diabetes, has the fewest side effects, and is the most beneficial for overall health. GRADE is a randomized clinical trial of participants diagnosed with type 2 diabetes within the past 10 years who are already on metformin. Participants will be randomly assigned to 1 of 4 commonly-used glucose-lowering drugs (glimepiride, sitagliptin, liraglutide, and basal insulin glargine), plus metformin, and will be followed for up to 7 years.

Proper citation: Glycemic Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (RRID:SCR_014384) Copy   


http://rc2resource.scripps.edu

Database portal for a project that aims to discover and characterize new molecular pathways that can be targeted pharmacologically to revert obesity-linked adipocyte defects that drive systemic insulin resistance and type 2 diabetes. It works to identify in tandem physiologically-relevant proteins and chemical tools in order to expedite their functional annotation and therapeutic validation.

Proper citation: Chemoproteomic identification and therapeutic validation of proteins of metabolic significance (RRID:SCR_015847) Copy   


http://monogenicdiabetes.uchicago.edu/mody-registry-2/

Research project that aims to learn more about the number of people who have monogenic diabetes, why and how it happens, and how best to treat it. Any adult or child with a known genetic cause of diabetes may join the MODY Registry.

Proper citation: Monogenic Diabetes Registry (RRID:SCR_015883) Copy   


http://www.ngsp.org

Project that aims to standardize Hemoglobin A1c test results to those of the Diabetes Control and Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS) which established the direct relationships between HbA1c levels and outcome risks in patients with diabetes.

Proper citation: National Glycohemoglobin Standardization Program (RRID:SCR_015885) Copy   


http://www.isletstudy.org/

Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation.

Proper citation: Clinical Islet Transplantation Study (RRID:SCR_001515) Copy   


http://www.t1diabetes.nih.gov/T1D-PTP/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.

Proper citation: Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) Copy   


  • RRID:SCR_009015

    This resource has 100+ mentions.

https://www.accordtrial.org/public

Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study.

Proper citation: ACCORD (RRID:SCR_009015) Copy   


http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx

Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk

Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy   


https://www.baderc.org/cores/metaboliccore/

Core in BADERC that provides services in consultation and teaching, use of DEXA scanner for determination of body fat and/or bone density, and use of Coulter Counter to measure cell number and cell size distribution.

Proper citation: Boston Area Diabetes Endocrinology Research Center Metabolic Physiology and Energy Balance Core Facility (RRID:SCR_008293) Copy   


http://harvard.eagle-i.net/i/0000012e-6d67-5282-55da-381e80000000

Core facility that provides the following services: Autoantibody determination, HLA typing and Genotyping for the best recognized susceptibility loci (INS, PTPN22, CTLA4).

The Human Sample Procurement Core will support translational research endeavors within the JDRF Center by providing the Center''s laboratories access to well-characterized blood samples from patients with diabetes at different stages of the disease. This availability will greatly facilitate the translational exploration of concepts and targets emerging from the basic research projects. Individuals with T1D (recent onset, long-standing Type-1 diabetes) and matched controls (healthy or T2D) will be recruited from the patient population at the Joslin Diabetes Center and neighboring institutions. The Core will perform and record a basic characterization of patients and their samples. This analysis will include a thorough evaluation of clinical characteristics from a diabetes and autoimmune standpoint, and an immunogenetic workup (outsourced to Joslin or other cores): autoantibody determination, HLA typing and genotyping for the best recognized susceptibility loci (INS, PTPN22, CTLA4). A relational database will be adapted to record all patient information, copies of which will be provided in a de-identified manner to the investigators.

Proper citation: HMS Human Sample Procurement Core Facility (RRID:SCR_009797) Copy   


http://harvard.eagle-i.net/i/0000012a-25bf-69ed-f5ed-943080000000

Core facility that provides the following services: Maintainence and dissemination of transgenic and mutant mice.

The Genetically Modified NOD Mouse Core provides Center investigators, as well as researchers elsewhere, with access to transgenic and mutant lines derived from the NOD mouse model: some will be generated within the Core; others are established lines of proven experimental value that are maintained in the Core. The Core will construct transgenic mice in strains that have a high susceptibility to diabetes (in particular in the NOD line). This includes trangenesis by conventional pronuclear injection or by delivery of RNAi cassettes on lentiviral vectors. The Core will also provide a panel of existing transgenic and mutant lines. These lines are chosen because of their established interest in allowing the dissection of immunological tolerance in Type 1 Diabetes, and in response to Center investigator needs.

Proper citation: HMS Genetically Modified NOD Mouse Core Facility (RRID:SCR_009796) Copy   


https://joslinresearch.org/drc-cores/Flow-Cytometry-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides cell sorting and flow cytometry services. Specific services include cell analysis, large object sorting,magnetic cell enrichment, and automatic cell counting.

Proper citation: Joslin Diabetes Center Flow Cytometry Core Facility (RRID:SCR_009878) Copy   


https://joslinresearch.org/drc-cores/Animal-Physiology-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides technically advanced physiological evaluation of metabolism in diabetes, obesity, and their associated complications in rodents for DRC investigators and outside users. It also provides training of investigators and trainees in several physiological procedures.

Proper citation: Joslin Diabetes Center Animal Physiology Core Facility (RRID:SCR_009876) Copy   


https://joslinresearch.org/drc-cores/Advanced-Microscopy-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for performing specific morphological procedures, providing training and access to equipment, maintaining the specialized microscopes, and giving advice and interpretation.

Proper citation: Joslin Diabetes Center Advanced Microscopy Core Facility (RRID:SCR_009875) Copy   



Can't find your Tool?

We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.

Can't find the RRID you're searching for? X
  1. Type 1 Diabetes Research Networks Resources

    Welcome to the T1D Resources search. From here you can search through a compilation of resources used by T1D and see how data is organized within our community.

  2. Navigation

    You are currently on the Community Resources tab looking through categories and sources that T1D has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.

  3. Logging in and Registering

    If you have an account on T1D then you can log in from here to get additional features in T1D such as Collections, Saved Searches, and managing Resources.

  4. Searching

    Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:

    1. Use quotes around phrases you want to match exactly
    2. You can manually AND and OR terms to change how we search between words
    3. You can add "-" to terms to make sure no results return with that term in them (ex. Cerebellum -CA1)
    4. You can add "+" to terms to require they be in the data
    5. Using autocomplete specifies which branch of our semantics you with to search and can help refine your search
  5. Save Your Search

    You can save any searches you perform for quick access to later from here.

  6. Query Expansion

    We recognized your search term and included synonyms and inferred terms along side your term to help get the data you are looking for.

  7. Collections

    If you are logged into T1D you can add data records to your collections to create custom spreadsheets across multiple sources of data.

  8. Sources

    Here are the sources that were queried against in your search that you can investigate further.

  9. Categories

    Here are the categories present within T1D that you can filter your data on

  10. Subcategories

    Here are the subcategories present within this category that you can filter your data on

  11. Further Questions

    If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.

X